U.S. Markets open in 8 hrs 10 mins

Alterity Therapeutics Limited (ATH.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.03000.0000 (0.00%)
As of 4:10PM AEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0300
Open0.0300
Bid0.0300 x 0
Ask0.0310 x 0
Day's Range0.0300 - 0.0310
52 Week Range0.0240 - 0.0540
Volume1,267,556
Avg. Volume9,522,515
Market Cap62.521M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateOct 28, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

    Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company's Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International Parkinson and Movement Disorder Society Virtual Congress 2021 being held September 17-22, 2021.

  • PR Newswire

    Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

    Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375. The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegen

  • PR Newswire

    Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

    Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2021 (Q4 FY21).